

# PKC $\zeta$ regulates Notch receptor routing and activity in a Notch signaling-dependent manner

Marika Sjöqvist<sup>1,2,\*</sup>, Daniel Antfolk<sup>1,2,\*</sup>, Saima Ferraris<sup>2</sup>, Vilma Rraklli<sup>3</sup>, Cecilia Haga<sup>1,2</sup>, Christian Antila<sup>1,2</sup>, Anders Mutvei<sup>4</sup>, Susumu Y Imanishi<sup>1</sup>, Johan Holmberg<sup>3,4</sup>, Shaobo Jin<sup>4</sup>, John E Eriksson<sup>1,2</sup>, Urban Lendahl<sup>4</sup>, Cecilia Sahlgren<sup>1,2,5</sup>

<sup>1</sup>Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, 20520 Turku, Finland; <sup>2</sup>Department of Biosciences, Åbo Akademi University, 20520 Turku, Finland; <sup>3</sup>Ludwig Institute for Cancer Research, Karolinska Institute, Box 240, SE-171 77 Stockholm, Sweden; <sup>4</sup>Department of Cell and Molecular Biology, Karolinska Institutet, SE-171 77 Stockholm, Sweden; <sup>5</sup>Department of Biomedical Engineering, Technical University of Eindhoven, 2612 Eindhoven, The Netherlands

**Activation of Notch signaling requires intracellular routing of the receptor, but the mechanisms controlling the distinct steps in the routing process is poorly understood. We identify PKC $\zeta$  as a key regulator of Notch receptor intracellular routing. When PKC $\zeta$  was inhibited in the developing chick central nervous system and in cultured myoblasts, Notch-stimulated cells were allowed to undergo differentiation. PKC $\zeta$  phosphorylates membrane-tethered forms of Notch and regulates two distinct routing steps, depending on the Notch activation state. When Notch is activated, PKC $\zeta$  promotes re-localization of Notch from late endosomes to the nucleus and enhances production of the Notch intracellular domain, which leads to increased Notch activity. In the non-activated state, PKC $\zeta$  instead facilitates Notch receptor internalization, accompanied with increased ubiquitylation and interaction with the endosomal sorting protein Hrs. Collectively, these data identify PKC $\zeta$  as a key regulator of Notch trafficking and demonstrate that distinct steps in intracellular routing are differentially modulated depending on Notch signaling status.**

**Keywords:** atypical PKC; endocytosis; Notch signaling; lysosome; Hrs

*Cell Research* (2014) 24:433–450. doi:10.1038/cr.2014.34; published online 25 March 2014

## Introduction

The Notch pathway regulates a cell-cell communication and thereby is important for control of cell differentiation in many different cell types. The complex proteolytic processing and intracellular routing of the Notch receptor are two cardinal features of the pathway [1, 2]. Notch signaling is initiated by the interaction between the cell-bound Notch receptors and transmembrane ligands on juxtaposed cells. This leads to two proteolytic cleavages of the Notch receptor: an extracellular site 2 (S2) cleavage conducted by ADAM metalloproteases, which generates a truncated transmembrane receptor form, Notch Extracellular Truncation (NEXT), and a

further processing of NEXT by the  $\gamma$ -secretase complex in the membrane. The second cleavage (at site 3, S3 cleavage) generates the Notch intracellular domain (Notch ICD or NICD), which translocates to the nucleus, interacts with the DNA-binding protein CSL (CBF1, Suppressor of Hairless, Lag-1) and activates expression of Notch downstream genes.

In contrast to the relatively simple molecular architecture, it is becoming increasingly apparent that regulation of Notch signaling is more complex and that endocytosis and trafficking of the Notch receptor are important constituents of the pathway [1, 2]. It is well known that Notch receptors can be internalized, but the underlying mechanisms and effects of receptor internalization on Notch signaling activity are poorly understood [3]. There are several reports advocating that endocytosis promotes Notch activation [4–7], while other studies suggest that intracellular trafficking exerts a negative effect [8–12]. Similarly, there are conflicting views on where S3 processing occurs. A number of reports indicate that S3

\*These two authors contributed equally to this work.

Correspondence: Cecilia Sahlgren

Email: cecilia.sahlgren@btk.fi

Received 8 May 2013; revised 17 December 2013; accepted 20 December 2013; published online 25 March 2014

cleavage occurs after receptor internalization [4, 7, 12–14], while other studies suggest that it may occur at the cell surface [12]. Furthermore, S3 processing at the cell surface versus in the endosomes may yield distinct N-termini on the resulting NICD, and may endow them with distinct properties [15]. Proper routing of the internalized Notch receptor may also be important for preventing ligand-independent activation, and Notch signaling defects are indeed linked to impaired endocytic trafficking and endosome acidification [4, 16]. The internalization step appears to be controlled by monoubiquitylation of the Notch receptor at the cell surface [4], followed by a deubiquitylation event, which is required for signaling activation [17]. Deltex, an E3 ubiquitin ligase, is a regulator of Notch internalization and processing, although whether it functions to enhance or reduce Notch signaling appears to be cell context-dependent [18–20]. Compromised sorting from early endosomes to multivesicular bodies (MVBs) or lysosomes, resulting from ESCRT/lethal giant larvae mutations in *Drosophila*, affects the Notch signaling [21], and Numb and Itch likely regulate postendocytic sorting events [22] (for review see [1, 3, 23]).

These findings point to a complex and dynamic regulation of Notch receptor intracellular routing, but it remains unknown as to how the distinct steps in the routing process from cell surface via internalization into endosomes and onwards to the nucleus are controlled. It is likely that additional proteins are involved in the control of Notch trafficking, and that regulation of routing modulates the Notch signaling output. Atypical protein kinase C (aPKC) may be an interesting candidate for control of Notch receptor intracellular trafficking and function, as there is an emerging view that aPKCs play a key role both in regulation of protein trafficking and in various differentiation processes. aPKCs play critical roles in cell polarization [24, 25], asymmetric cell division [26, 27] and migration [28–30], and also link cell polarity cues to differentiation [26, 27, 31–34]. aPKCs are critical regulators of the organization of the apical-basal axis in epithelial cells, a process in which aPKC functions together with PAR-3 and PAR-6 in a complex, and this PAR-3/PAR-6/aPKC complex is pivotal for establishing cellular polarity and organizing cellular junctions [35–38]. aPKC also regulates the Cdk5 kinase during myoblast differentiation [39] and PAR1-aPKC antagonism regulates neurogenesis through modulation of Notch signaling [40]. PAR1 (negatively regulated by aPKC) acts on the E3 ubiquitin ligase Mindbomb to regulate Notch ligands in the signal-sending cells. Polarity proteins are key regulators of endocytic trafficking [28, 41], and can function to segregate proteins to the apical or basal side through

regulation of intracellular trafficking [42].

In this report, we unravel a novel role of atypical PKC $\zeta$  (aPKC $\zeta$ ) in control of intracellular localization of Notch1 and Notch signaling output. We demonstrate that inhibition of aPKC $\zeta$  reduces the ability of Notch to keep cells undifferentiated in the chick central nervous system (CNS) *in vivo* and in myogenic progenitors *in vitro*. aPKC $\zeta$  interacts with and phosphorylates membrane-tethered but not cytoplasmic forms of Notch1, and controls Notch1 trafficking with different outcomes depending on the Notch activation state. When Notch signaling is not activated, aPKC $\zeta$  regulates the transition of Notch from cell surface and the secretory Golgi/ER pathway to intracellular vesicles. In contrast, when Notch signaling is active, aPKC $\zeta$  governs the routing from intracellular vesicles to the cell nucleus, leading to augmented activation of the Notch signaling pathway. These data identify aPKC $\zeta$  as a key regulator of intracellular localization of Notch receptor and Notch signaling output, and show that intracellular routing of the Notch receptor is differentially modulated depending on the activity status of the Notch signaling pathway itself.

## Results


### *Inhibition of aPKC $\zeta$ reduces the capacity of Notch to negatively regulate neuronal differentiation in the developing CNS*

It is well established that Notch signaling in many cellular contexts inhibits differentiation and maintains cells in a more undifferentiated state. This has been extensively explored in the developing chick CNS where expression of NICD maintains CNS progenitor cells close to the ventricle and inhibits their maturation to early, Tuj1-positive neurons located at the marginal zone of the neural tube [43]. We tested whether PKC $\zeta$  influenced Notch-mediated block of neuronal differentiation in the chick CNS. To this end, we engineered a membrane-tethered activated form of Notch1, Notch1 $\Delta$ E, that was Myc-tagged and linked to a nuclear form of EGFP via an IRES sequence to trace expression. We confirmed that the construct, CAG-Notch1 $\Delta$ E-Myc-IRES-EGFP, was expressed and that the expression indeed resulted in robust activation of a reporter construct containing 12 CSL-binding motifs (12 $\times$ CSL-dsRED) [44] (Figure 1A–1C). To explore a possible role of PKC $\zeta$  in regulating Notch activity and control of stem cell differentiation, we next combined expression of CAG-Notch1 $\Delta$ E-Myc-IRES-EGFP with pharmacological inhibition of PKC $\zeta$  activity using a pseudosubstrate peptide (PS; Myr-SIYR-RGARRWRKL). The inhibitor was injected into the ventricular space of HH stage 10 chick embryos and CAG-

Notch1ΔE-Myc-IRES-EGFP was electroporated. Expression of CAG-Notch1ΔE-Myc-IRES-EGFP in the absence of inhibitors led to a marked reduction in the number of Tuj1-positive cells compared with the other side of

the neural tube without Notch1ΔE overexpression, and a localization of the Notch-expressing cells close to the ventricle (Figure 1D and 1F), which is in keeping with previous observations [43]. In contrast, when CAG-Notch1ΔE-Myc-IRES-EGFP was expressed in the presence of PKCζ inhibitor, we observed a partial shift of Notch-expressing cells (visualized by EGFP) to the marginal zone of the neural tube, and an increased overlap between EGFP and Tuj1 expression (Figure 1E). This suggests that the activity of Notch was reduced, allowing electroporated cells to differentiate despite expressing an activated form of Notch. However, the pharmacological inhibition of PKCζ was not sufficient to significantly reduce the 12×CSL-dsRED reporter activity (data not shown), which is likely an effect of the expression of very high levels of Notch1ΔE following electroporation.

Embryos receiving the PKCζ inhibitor exhibited an altered intracellular localization of Notch1 (Figure 1G–1I, Supplementary information, Figure S1A and S1B). In the absence of the inhibitor, Notch1, visualized by Myc immunostaining, was evenly distributed between the nucleus and the cytoplasm, where it was expressed in a speckled pattern (Figure 1G–1I, Supplementary informa-



**Figure 1** Regulation of Notch1 by PKCζ affects *in vivo* neuronal differentiation, protein localization and expression. **(A–C)** Cells co-electroporated with CAG-Notch1 E-myc-IRES-EGFP and the 12×CSL-DsRed reporter expressed eGFP (nuclear because CAG-Notch1ΔE-myc-IRES-EGFP contains a nuclear localization signal (NLS)) **(A)** and DsRed **(B)**, which overlay in **C**, showing that Notch1ΔE efficiently activates Notch signaling within 24 h. **(D)** Cells expressing CAG-Notch1ΔE-myc-IRES-EGFP (green) did not show staining for the neuronal marker Tuj1 (red, inset) and showed reduced migration out to the marginal zone, 40 h after electroporation. **(E)** In embryos injected with the aPKC inhibitor, Notch1ΔE-expressing cells (green, inset) exhibited increased expression of Tuj1 (red, inset). **(F)** Quantification of the ratio of GFP<sup>+</sup> cells that also expressed Tuj1 40 h after electroporation with CAG-Notch1ΔE-myc-IRES-EGFP in the presence or absence of the aPKC inhibitor. **(G)** Twenty-four hours after electroporation, cells expressing CAG-Notch1ΔE-myc-IRES-EGFP (green, inset) exhibited nuclear Myc localization in approximately half of the Myc-positive cells (red, inset). **(H)** In the presence of the aPKC inhibitor, nuclear localization of Myc was significantly reduced (red, inset). **(I)** Quantification of the proportion of cells with nuclear-localized Myc compared to the total number of Myc-expressing cells. **(J)** CAG-Notch1ΔE-myc-IRES-EGFP-expressing cells (green, inset) retaining Myc (red, inset) immunoreactivity 40 h post electroporation. **(K)** CAG-Notch1ΔE-myc-IRES-EGFP-expressing cells (green, inset) treated with aPKC inhibitor exhibited reduced Myc immunoreactivity (red, inset) 40 h after electroporation. **(L)** Quantification of the number of GFP-expressing cells that exhibit Myc immunoreactivity. Data are represented as mean ± SEM. \**P* < 0.05, \*\**P* < 0.01, Student's *t*-test. Scale bars, upper 45 μm, lower (inset) 15 μm.



tion, Figure S1A and S1B). This is indicative of a location in intracellular vesicles, which is in keeping with the established view on Notch intracellular distribution. In contrast, the presence of PKC $\zeta$  inhibitor reduced the levels of nuclear Notch protein and increased the ratio of Myc immunoreactivity in the cytoplasm (Figure 1H and 1I).

We next examined whether Notch protein levels were affected by PKC $\zeta$  by comparing the number of cells that had at one point expressed Notch1 $\Delta$ E (EGFP-expressing cells) with the number of cells that contained Notch1 $\Delta$ E, or its derivative NICD (Myc immunoreactivity). Forty hours after electroporation, embryos treated with PKC $\zeta$  inhibitor exhibited a reduction in the proportion of EGFP-expressing cells that also exhibited Myc immunoreactivity (Figure 1J–1L).

Taken together, these data indicate that blocking PKC $\zeta$  activity mitigates Notch-mediated blocking of neuronal differentiation. Inhibition of PKC $\zeta$  also caused a partial re-localization of Notch from the nucleus to the cytoplasm and over time a reduction in the total levels of Notch protein.

#### *aPKC $\zeta$ interacts with membrane-tethered but not cytoplasmic forms of Notch1 and phosphorylates Notch1*

To explore the mechanistic basis for the relationship between PKC $\zeta$  and Notch1 *in vivo* (Figure 1), we first tested whether PKC $\zeta$  interacts with Notch1. The endogenous Notch1 was immunoprecipitated from non-differentiating and differentiating C2C12 cells, and in both cases PKC $\zeta$  was shown to interact with Notch1 (Figure 2A). We next addressed whether the interaction was dependent on the Notch signaling status. Notch1 was immunoprecipitated before and after activation by immobilized Delta-like 1 ligand (Dll1) and in the presence or absence of  $\gamma$ -secretase inhibitor (GSI) treatment. PKC $\zeta$  interacted with both the ligand-activated and non-activated Notch1, but the interaction was stronger in GSI-treated cells when Notch1 was activated by the ligands (Figure 2B).


We next assessed whether PKC $\zeta$  interacted with Notch1 $\Delta$ E. PKC $\zeta$  interacted with Notch1 $\Delta$ E, and like in the full-length receptor situation, GSI treatment enhanced the interaction (Figure 2C). We then addressed whether PKC $\zeta$  also interacted with NICD. In contrast to the interaction observed when Notch1 was immunoprecipitated with the C20 antibody that recognizes all forms of Notch1 (full length, S2 and S3 cleaved forms) (Supplementary information, Figure S2), no interaction was seen when NICD was immunoprecipitated from cells transfected with Notch1 $\Delta$ E using the cleaved-Notch antibody that only recognizes the S3 cleaved form (Figure 2D left and Supplementary information, Figure S2).

We further tested the interaction between PKC $\zeta$  and a *de novo* generated NICD, which is structurally identical to the intracellular domain of Notch1, but is produced in the cytoplasm and thus never membrane-tethered. In contrast to the interaction observed with Notch1 $\Delta$ E, no interaction was seen between NICD and PKC $\zeta$  (Figure 2D, right and below).

To determine whether Notch1 serves as a direct enzymatic target for PKC $\zeta$ , we analyzed whether Notch1 immunoprecipitated from C2C12 cells could be *in vitro* phosphorylated by recombinant PKC $\zeta$ . We found that Notch1 was phosphorylated by PKC $\zeta$ , and no phosphorylation was observed when PKC $\zeta$  was omitted (Figure 2E). Mass spectrometry analysis of the phosphorylated Notch1 identified Serine (S) 1791, located in the intracellular domain, as the predominant PKC $\zeta$  phosphorylation site (Supplementary information, Figure S3A). The S1791 residue is highly conserved from amphibia to human, and is present in both Notch1 and 2 (Figure 2F). The site is however not found in *Drosophila* or *Caenorhabditis elegans* and is also absent from Notch3 and 4 in vertebrates (Supplementary information, Figure S4). Mass spectrometry analysis of Notch1 phosphorylated *in vitro* with PKC $\iota$  yielded similar results (Supplementary information, Figure S3B), showing that different aPKC isoforms can phosphorylate Notch at the same residue. Taken together, these data indicate that Notch is a novel target for phosphorylation by PKC $\zeta$  and that PKC $\zeta$  interacts with membrane-tethered full-length and Notch1 $\Delta$ E forms of the receptor but not with activated forms of the Notch receptors that are produced in the cytoplasm and thus not membrane-localized.

#### *aPKC $\zeta$ increases production of NICD, enhances Notch signaling and relocates Notch1 from endosomes to the nucleus*

We then tested whether PKC $\zeta$  affected Notch signaling output. Notch signaling was activated in 293 HEK cells stably expressing the full-length Notch1 (293FLN1) by culturing the cells on immobilized Jagged1 ligand, and the downstream signaling was measured by a reporter construct with multimerized CSL-binding sites linked to the luciferase gene (12 $\times$ CSL-luc) [45]. 12 $\times$ CSL-luc reporter activity was enhanced by culturing the 293FLN1 cells on immobilized Fc-Jagged1 as compared to Fc-IgG as control, and transfection of a constitutively active form of PKC $\zeta$  (caPKC $\zeta$ ) led to a further increase in reporter activity (Figure 3A). Reporter activity resulting from transfection of Notch1 $\Delta$ E was similarly enhanced by caPKC $\zeta$  (Figure 3B). In contrast, when NICD was transduced, there was no further activation in the presence of caPKC $\zeta$  (Figure 3C), in keeping with the ob-



**Figure 2** Notch1 interacts with PKC $\zeta$  at the membrane. **(A)** Untransfected C2C12 cells undergoing differentiation were harvested at different time points and subjected to immunoprecipitation (IP) using a Notch1 antibody (C20 goat). Immunoblotting was performed with an antibody against PKC $\zeta$ . **(B)** Immunoprecipitation of Notch1 from C2C12 cells stably expressing the full-length Notch1 receptor and transfected with constitutively active PKC $\zeta$  (caPKC $\zeta$ ) and grown on immobilized DII1 or Fc-IgG as control. The cells were treated with the  $\gamma$ -secretase inhibitor (GSI) DAPT for 24 h prior to harvesting. Immunoblotting was performed with an antibody against PKC $\zeta$ . **(C)** Immunoprecipitation of Notch1 (C20 goat) from HeLa cells transfected with Notch1ΔE and caPKC $\zeta$  and treated with DAPT or vehicle control for 24 h. Immunoblotting was performed with an antibody against PKC $\zeta$ . **(D)** Left: Immunoprecipitation of NICD (using cleaved-Notch antibody) from 293 HEK cells transfected with Notch1ΔE and caPKC $\zeta$ . Immunoblotting was performed using an antibody against PKC $\zeta$ . Right: Immunoprecipitation of PKC $\zeta$  using an antibody against the His tag of PKC $\zeta$  from 293 HEK cells transfected with NICD and PKC $\zeta$ . Immunoblotting was performed using an antibody against Notch1 (C20 goat). Below: Immunoprecipitation of Notch1 ICD using a GFP antibody from 293 HEK cells transfected with a GFP-tagged NICD (NICD<sup>(GFP)</sup>) and caPKC $\zeta$ . Immunoblotting was performed using an antibody against PKC $\zeta$ . **(E)** Autoradiograph of Notch1 phosphorylated *in vitro* by recombinant PKC $\zeta$ . Notch1 was immunoprecipitated (C20 goat) from C2C12 cells. Recombinant PKC $\zeta$  and <sup>32</sup>P ATP were added to the immunoprecipitate. The reaction was incubated at 37 °C for 15 min and stopped by adding Laemmli Sample Buffer and boiling for 5 min. The samples were separated by SDS-PAGE and the proteins were transferred to a nitrocellulose membrane. The upper image shows an autoradiograph of the membrane and the lower image shows an immunoblot of the same membrane performed after the radioactive signal had decayed. **(F)** Sequence alignment shows that the phosphorylation site S1791 is highly conserved in different species and is also present in Notch2.

served lack of interaction between PKC $\zeta$  and NICD (Figure 2D). Further, caPKC $\zeta$  did not enhance the reporter activity induced by Notch1ΔE carrying a mutation in K1749 (Notch1ΔE<sup>K1749R</sup>) (Figure 3D). K1749 has been suggested to be critical for monoubiquitylation and subsequent S3-processing of Notch1ΔE [4]. An alternative

view is that the S3-cleavage site is altered, which generates a short-lived NICD. Our results are compatible with both models.

Co-transfection of Notch1ΔE with caPKC $\zeta$  or caPKC $\iota$  led to increased levels of NICD in a dose-dependent manner (Figure 3E), indicating that caPKCs trigger an

increased production of NICD from Notch1 $\Delta$ E. To verify whether the observed increase in NICD levels requires aPKC $\zeta$  kinase activity, we used two dominant-negative mutants of the kinases (dnPKC $\zeta$  and dnPKC $\iota$ ). The dominant-negative mutants did not enhance Notch processing, demonstrating that kinase activity is required (Figure 3F). The caPKC $\zeta/\iota$ -induced increase in NICD production was blocked by GSI, suggesting that aPKC $\zeta/\iota$  operate upstream of S3 cleavage (Figure 3F).

The observation that inhibition of PKC $\zeta$  shifted the localization of Notch1 $\Delta$ E towards the cytoplasm *in vivo* (Figure 1 and Supplementary information, Figure S1) suggests that caPKC $\zeta/\iota$ -enhanced S3 cleavage and Notch activation may occur in endosomes. In keeping with this, blocking dynamin-induced internalization of the Notch receptor by dynasore [46] in cells expressing caPKC $\zeta$  resulted in reduced amounts of NICD following ligand-induction (Figure 3G). To further extend these observations, we investigated the possible role of aPKC in intracellular Notch localization. In 293 HEK cells, Notch1 was predominantly localized in intracellular vesicles and only to a smaller extent in the nucleus (Figure 3H). Co-expression of Notch1 $\Delta$ E with caPKC $\zeta$  shifted the Notch immunoreactivity to the nucleus, whereas expression of dnPKC $\zeta$  resulted in Notch immunoreactivity predominantly in vesicles in the cytoplasm (Figure 3H). A similar shift in intracellular localization was observed in C2C12 cells, in which dnPKC $\zeta$  enhanced the presence of Notch immunoreactivity in cytoplasmic vesicles, at the expense of nuclear localization (Figure 3I, left). Expression of caPKC $\zeta$ , but not dnPKC $\zeta$ , resulted in an increase in NICD expression as demonstrated by western blotting (Figure 3I, right). The localization of Notch1 in the nucleus in PKC $\zeta$ -expressing cells was shifted to cytoplasmic vesicles upon GSI treatment, suggesting that PKC $\zeta$  operates upstream of endosomal S3 cleavage and nuclear translocation (Supplementary information, Figure S5). Together, these data suggest that under conditions of active Notch signaling, aPKC further enhances Notch signaling by increasing production of NICD from Notch1 $\Delta$ E and shifting the localization of Notch1 from intracellular vesicles to the nucleus, which corroborates the *in vivo* observations.

Numb is a negative regulator of Notch signaling [47] and regulates Notch endocytosis [48]. Numb has recently been shown to be phosphorylated by aPKCs [49], which prompted us to test whether the effect of PKC $\zeta$  on Notch was influenced by Numb. Overexpression of Numb reduced Notch activity (Supplementary information, Figure S2), in keeping with previous reports [48]. Importantly, Numb overexpression did override the enhancing effect of PKC $\zeta$  as expression of Numb together with caPKC $\zeta$  reduced signaling from Notch1 $\Delta$ E (Supplemen-


tary information, Figure S6). Furthermore, expression of Numb combined with blocking of PKC $\zeta$  led to a stronger inhibition of Notch activity as compared to expression of Numb or blocking of PKC $\zeta$  alone (Supplementary information, Figure S6). These data suggest that Numb and PKC $\zeta$  affect Notch signaling at distinct steps.

#### *The PKC $\zeta/\iota$ phosphorylation site S1791 is critical for NICD production, Notch intracellular localization and Notch signaling*


To assess the effect of PKC $\zeta/\iota$ -mediated phosphorylation of Notch1 at S1791 (Figure 2 and Supplementary information, Figure S3), we generated PKC $\zeta/\iota$ -phosphorylation-deficient and phosphomimetic forms of Notch1 $\Delta$ E: Notch1 $\Delta$ E<sup>S1791A</sup> and Notch1 $\Delta$ E<sup>S1791E</sup>, respectively. In addition, we generated a phosphomimetic form of the full-length receptor Notch1FLN<sup>S1791E</sup> (Figure 4A). Treatment with GSI, which blocks S3 cleavage, revealed that although similar amounts of uncleaved Notch1 $\Delta$ E protein were produced from Notch1 $\Delta$ E and Notch1 $\Delta$ E<sup>S1791A</sup> (Figure 4B, upper), expression of Notch1 $\Delta$ E<sup>S1791A</sup> led to a significant decrease in the level of NICD in 293 HEK cells (Figure 4B, lower). Consistently, 12 $\times$ CSL-luc activity in response to Notch1 $\Delta$ E<sup>S1791A</sup> expression was decreased compared with Notch1 $\Delta$ E expression (Figure 4C). Conversely, expression of the phosphomimetic mutant Notch1 $\Delta$ E<sup>S1791E</sup> resulted in an enhanced production of NICD (Figure 4B, lower) and 12 $\times$ CSL-luc reporter activity (Figure 4C) compared with Notch1 $\Delta$ E expression. Interestingly, when caPKC $\zeta$  was co-expressed with Notch1 $\Delta$ E, 12 $\times$ CSL-luc reporter activity was further increased, whereas caPKC $\zeta$  did not enhance the reporter activity from Notch1 $\Delta$ E<sup>S1791A</sup> (Figure 4D). On the contrary, the reporter activity was reduced which might reflect downregulation of endogenous Notch activity. Both Dll1 (Figure 4E) and Jagged1 (data not shown) induced an enhanced activation of the phosphomimetic form of the full-length receptor Notch1FLN<sup>S1791E</sup> (Figure 4E) and higher levels of NICD were detected (Supplementary information, Figure S7) as compared to wild-type full-length Notch1. This effect was dose-dependent, i.e., more pronounced at high concentrations of ligands (Figure 4F).

To assess whether the increased level of NICD following caPKC $\zeta$  expression was due to altered stability of NICD, we performed a cycloheximide (CHX) chase experiment. Expression of caPKC $\zeta$  did not affect the decrease rate of NICDs produced from the various Notch1 $\Delta$ E forms (Supplementary information, Figure S8A). Treatment with the proteasome inhibitor MG132 yielded no significant difference in the degradation rate of the NICDs generated from different mutants (Supplementary information, Figure S8B). Further, caPKC $\zeta$





**Figure 3** PKC $\zeta$  increases NICD levels and enhances Notch signaling. **(A)** Notch signaling activity was measured using a luciferase-based reporter system (12 $\times$ CSL-luc). 293 HEK cells stably expressing full-length Notch1 (293FLN1) were transfected with 12 $\times$ CSL-luc, CMV- $\beta$ -galactosidase and caPKC $\zeta$  or empty vector and grown on immobilized recombinant Jagged1 or Fc-IgG (FC) control. **(B–D)** The luciferase-based reporter system was used to measure the signaling activity of Notch1 $\Delta$ E and NICD in the presence and absence of caPKC $\zeta$ . 293 HEK cells were transfected with 12 $\times$ CSL-luc, CMV- $\beta$ -galactosidase, Notch1 $\Delta$ E **(B)**, NICD **(C)** or the monoubiquitylation mutant Notch1 $\Delta$ EK1749R **(D)** and caPKC $\zeta$  or empty vector. The figures in **A–D** represent means from three separate experiments. Error bars indicate SD. **(E)** Western blot analysis using a cleaved-Notch antibody against NICD in 293 HEK cells transfected with Notch1 $\Delta$ E and increasing amounts of caPKC $\zeta$ , caPKC $\zeta$  or empty vector. **(F)** Western blot using a cleaved-Notch antibody in 293 HEK cells transfected with Notch1 $\Delta$ E and caPKC $\zeta$ , dnPKC $\zeta$ , caPKC $\zeta$  or dnPKC $\zeta$ . The cells were treated with GSI DAPT for 24 h prior to harvesting. **(G)** Western blot using a cleaved-Notch antibody on caPKC $\zeta$ -transfected 293FLN1 cells grown on immobilized Jagged1 in the presence or absence of the dynamin inhibitor Dynasore (80  $\mu$ M, 2 h). **(H)** 293 HEK cells transfected with Notch1 $\Delta$ E and caPKC $\zeta$  or dnPKC $\zeta$  were stained with antibodies against Notch1 and PKC $\zeta$  and counterstained with DAPI. **(I)** Representative microscopy images showing localization of Notch1 in C2C12 cells transfected with caPKC $\zeta$  or dnPKC $\zeta$  and Notch1 $\Delta$ E. The western blot shows expression of NICD, Notch1 and PKC $\zeta$  in C2C12 cells transfected with Notch1 $\Delta$ E and caPKC $\zeta$  or dnPKC $\zeta$ . Heat shock protein 70 (Hsc70) was used as a loading control. Scale bars in **H** and **I**, 10  $\mu$ m.



**Figure 4** Phosphorylation at S1791 enhances Notch signaling. **(A)** Schematic depiction of the wild-type and mutant Notch1ΔE and the full-length Notch1 (Notch1FLN). **(B)** Western blot with antibodies against Notch1 to detect Notch1ΔE and NICD in 293 HEK cells transfected with Notch1ΔE, Notch1ΔE<sup>S1791A</sup> or Notch1ΔE<sup>S1791E</sup>. The cells were treated with the  $\gamma$ -secretase inhibitor (GSI) or vehicle control (Control) for 24 h. **(C)** Notch signaling activity was measured using a luciferase-based reporter system (12 $\times$ CSL-luc). 293 HEK cells were transfected with 12 $\times$ CSL-luc and Notch1ΔE, Notch1ΔE<sup>S1791A</sup>, Notch1ΔE<sup>S1791E</sup> or empty vector. **(D)** Notch signaling activity in cells co-transfected with caPKC $\zeta$  and Notch1ΔE or Notch1ΔE<sup>S1791A</sup>. **(E)** Notch signaling activity in cells transfected with Notch1FLN or Notch1FLN<sup>S1791E</sup> and activated by immobilized Dll1 ligands. **(F)** Notch signaling activity in cells transfected with Notch1FLN or Notch1FLN<sup>S1791E</sup> and activated by various concentrations of immobilized Dll1 ligands. For the lower concentration, the conditioned medium containing Dll1 was diluted 1/3 before immobilization of ligand. Data represent a mean from three separate experiments. Error bar indicates SD and statistical significance is denoted as \*\* $P < 0.01$ , \* $P < 0.05$ .

did not significantly affect the stability of NICD in cells transfected with caPKC $\zeta$  and NICD (Supplementary information, Figure S8C). Taken together, these data suggest that NICD stability is not altered by aPKC $\zeta$ .

Upon blocking of lysosomal function, the levels of Notch1ΔE<sup>S1791A</sup> increased significantly, whereas the levels of Notch1ΔE only increased slightly and the levels of

Notch1ΔE<sup>S1791E</sup> showed no change (Supplementary information, Figure S8E). Blocking of lysosomal degradation during a CHX chase inhibited the reduction in the level of Notch1ΔE<sup>S1791A</sup> but not that of Notch1ΔE (Supplementary information, Figure S8F). This is in line with the data that the interaction between Notch1 and lysosomal protein LAMP1 was enhanced and Notch1 accumulated



in lysosomes upon PKC $\zeta$  inhibition (Figure 5G-5H). These observations also support the notion that NEXT is contained in endocytic vesicles, routed to lysosomes and degraded when PKC $\zeta$  is inactivated. Furthermore, the observation that aPKC $\zeta$  does not directly alter the stability of NICD but that inhibition of aPKC $\zeta$  leads to lysosomal routing and degradation of Notch is in keeping with the *in vivo* observations that Notch1 accumulated in vesicles and the number of Notch1-expressing cells went down upon aPKC $\zeta$  inhibition (Figure 1).

We next assessed the intracellular localization of the different Notch1 $\Delta E$  forms. Notch1 $\Delta E$  and Notch1 $\Delta E^{S1791E}$  showed pronounced nuclear localization with limited immunolabeling of intracellular vesicles (Figure 5A). In contrast, Notch1 $\Delta E^{S1791A}$  was localized predominantly in cytoplasmic vesicles with very limited nuclear localization (Figure 5A), which resembles the distribution pattern of Notch1 in cells co-expressing Notch1 $\Delta E$  and dnPKC $\zeta$  (Figure 3H) or in the chick CNS upon pharmacological inhibition of PKC $\zeta$ . Consistently, the amount of NICD protein in the nucleus was indeed increased when the phosphomimetic mutant Notch1 $\Delta E^{S1791E}$ , not Notch1 $\Delta E^{S1791A}$ , was expressed compared with wild-type Notch1 $\Delta E$  overexpression (Figure 5B). The purity of the nuclear fraction was demonstrated by the absence of markers for Golgi and endoplasmic reticulum (Supplementary information, Figure S9). A similar increase in the percentage of cells with activated nuclear Notch1 was observed for Notch1 $\Delta E^{S1791E}$  (Figure 5C).

To explore which type of intracellular vesicles Notch1 was localized to, we analyzed whether the phosphomimetic and phosphodeficient forms of Notch1 $\Delta E$  interacted with the endosomal proteins Rab5, Rab7 and Lamp1. Rab5 is a marker for early endosomes, while Rab7 and Lamp1 are associated with late endosomes and late endosomal/lysosomal compartment, respectively [50]. Both phosphomimetic and phosphodeficient forms of Notch1 $\Delta E$  were present in Rab5- and Rab7-positive vesicles (Figure 5D). Further, all three Notch1 $\Delta E$  forms interacted with both Rab5 and Rab7, although Notch1 $\Delta E^{S1791E}$  showed a somewhat reduced interaction with Rab7 (Figure 5E). Notch1 $\Delta E^{S1791A}$  showed enhanced interaction with Lamp1, as compared to Notch1 $\Delta E$  (Figure 5F). Knockdown of PKC $\zeta$  mRNA expression by siRNA enhanced the interaction between endogenous Notch1 and Lamp1 in C2C12 cells (Figure 5G). Similarly, pharmacological inhibition of PKC $\zeta$  for 24 h led to accumulation of Notch1 immunoreactivity in Lamp1-positive late endosomes/lysosomes but not in EEA1-positive early endosomes (Figure 5H). This is in line with the data showing enhanced lysosomal degradation of phosphodeficient forms of Notch1 (Supplementary

information, Figure S8). Taken together, these data indicate that PKC $\zeta$ -mediated phosphorylation of Notch1 promotes its processing in late endosomes/lysosomes and thereby enhances nuclear translocation of Notch1, and conversely, blocking of PKC $\zeta$  results in Notch1 accumulation in Lamp1-positive late endosomes/lysosomes, eventually leading to degradation of the ligand-activated Notch1.


#### *An aPKC $\zeta$ phosphorylation-deficient Notch1 $\Delta E$ mutant does not block myogenic differentiation*

Notch keeps myogenic progenitors in an undifferentiated state and blocks differentiation to myotubes [45, 51, 52]. We next tested whether the phosphorylation of Notch1 at S1791 by aPKC $\zeta$  was important for Notch1 control of myogenic differentiation. When aPKC $\zeta$  was pharmacologically inhibited in primary myoblasts or C2C12 cells (data not shown), a reduction in the amount of NICD was observed (Figure 6A). Pharmacological inhibition of aPKC $\zeta$  also resulted in a pronounced increase in the number of cells expressing the differentiation marker myosin heavy chain (MHC) 48 h after induction of differentiation in primary myoblasts (Figure 6B). Further, downregulation of PKC $\zeta$  in C2C12 myoblasts reduced Notch activity and caused a precocious upregulation of MHC levels (Figure 6C). Conversely, when C2C12 myoblast cells were shifted to differentiation-promoting conditions, overexpression of caPKC $\zeta$  or caPKC $\iota$  resulted in increased NICD levels (Figure 6D and Supplementary information, Figure S10). An increase in the proportion of C2C12 cells expressing MHC was observed after Notch1 $\Delta E^{S1791A}$  expression: 29% of Notch1 $\Delta E^{S1791A}$ -expressing cells were MHC-positive, while only 10% of Notch1 $\Delta E$ -expressing cells expressed MHC at 48 h of differentiation (Figure 6E). At 72 h, there were 71% MHC-positive cells for Notch1 $\Delta E^{S1791A}$  as compared to 14% for Notch1 $\Delta E$  expression (Figure 6E). In conclusion, these data show that aPKC $\zeta$  activity influences myogenic differentiation, and that the phosphorylation-deficient Notch1 $\Delta E$  mutant is unable to block myogenic differentiation.


#### *PKC $\zeta$ promotes a shift in Notch receptor distribution from the cell surface to endosomes in the non-activated state*

The data above demonstrate that under conditions of activated Notch signaling, either by ligand stimulation or expression of Notch1 $\Delta E$ , PKC $\zeta$  augments the Notch signaling response. As PKC $\zeta$  interacted with the full-length Notch1 that was not ligand-activated (Figure 2), it is possible that PKC $\zeta$  may also exert an effect on Notch1 in the non-activated state. We therefore tested whether


A




B




C




D




E




F



G



H



PKC $\zeta$  affected full-length Notch1 distribution in the non-activated state, i.e., when cells were cultured very sparsely and did not contact each other, thus avoiding cell-cell interaction and activation of Notch. Under these conditions, expression of caPKC $\zeta$  in 293 HEK cells (293FLN1 cells) or in C2C12 cells, both stably expressing full-length Notch1, resulted in a shift of Notch1 distribution from the cell surface to intracellular vesicles (Figure 7A and 7B). To further assess receptor internalization, we labeled Notch1 on the cell surface with a fluorescently tagged antibody at 4 °C. After transfer to 37 °C, the internalization of Notch1 was determined by flow cytometry, and cells transfected with caPKC $\zeta$  showed higher internalization of Notch1 than control cells (Figure 7C).

The low level of NICD observed in sparsely cultured C2C12 cells as well as the low 12 $\times$ CSL-luc basal activity were further reduced by caPKC $\zeta$  (Figure 7D). Receptor ubiquitylation is an important event in receptor internalization and degradation, and we tested whether aPKC-mediated Notch1 internalization was accompanied by Notch1 ubiquitylation. Overexpression of both aPKC $\epsilon$  and aPKC $\zeta$  in sparsely cultured C2C12 cells led to increased ubiquitylation of Notch1 when lysosomal maturation or endosomal trafficking was blocked by chloroquine (Figure 7E). As an alternative measure of receptor internalization, we explored whether Notch1 interacted with Hrs, which is an endosome-associated ubiquitin-binding protein involved in cargo selection and important for endosomal sorting. Transfection of caPKC $\zeta$  resulted in an enhanced interaction between Notch1 and Hrs in the non-activated state (Figure 7F). Although aPKC enhanced internalization of Notch1, this was not associated with increased lysosomal degradation, as chloroquine treatment resulted in a similar increase in Notch1 protein levels in the absence and presence of PKC $\zeta$  (Figure 7G). Unexpectedly, in a cell surface protein biotinylation experiment, we did not observe a decrease in Notch1 at the surface of cells expressing PKC $\zeta$  (Figure 7H). While these data indicate that a full-length Notch receptor not


engaged in Notch signaling could be internalized to endosomes, we attempted to extend the analysis to address whether a full-length receptor that never even reaches the cell surface could be relocalized to endosomes by aPKC. To this end, we engineered a full-length Notch1 lacking the two ligand-interacting EGF repeats 10 and 11 (FLN1 $\Delta$ EGF10-11), which was trapped in the ER/Golgi compartment and therefore unable to engage in activation *in trans* by ligands (Supplementary information, Figure S11). Co-expression with PKC $\zeta$  resulted in a shift in intracellular localization of Notch1, which was predominantly localized to endosomal vesicles (Supplementary information, Figure S11). This indicates that full-length Notch receptors can be moved from the exocytic pathway to endosomes and that aPKC presumably interacts with Notch receptors early in the process. In conclusion, these data suggest that when Notch1 is in the non-activated state, aPKC $\zeta$  serves to shift the distribution of Notch receptors from the cell surface and the secretory pathway to intracellular vesicles, which is not accompanied by enhanced Notch signaling nor enhanced degradation.

## Discussion

In Notch signaling, receptor internalization is an integral part of the intracellular signaling cascade. However, it is still largely unknown how endocytosis and intracellular routing of the Notch receptor are controlled. In this report, we demonstrate that PKC $\zeta$  interacts with and phosphorylates Notch1 and acts as a novel regulator of Notch receptor trafficking. PKC $\zeta$  controls two distinct steps in Notch receptor intracellular routing, depending on the Notch signaling state. During active Notch signaling, i.e., after ligand stimulation or after expression of an activated membrane-tethered form of Notch, PKC $\zeta$  enhances production of NICD and shifts the localization of Notch from late endosomes to the nucleus, leading to elevated Notch signaling. In contrast, when the Notch re-

**Figure 5** Phosphorylation at S1791 affects intracellular localization of Notch1. **(A)** Representative microscopy images showing the localization of Notch1 $\Delta$ E, Notch1 $\Delta$ E<sup>S1791A</sup> or Notch1 $\Delta$ E<sup>S1791E</sup>. **(B)** Western blot using an antibody against NICD of nuclear extracts isolated from cells transfected with Notch1 $\Delta$ E<sup>S1791A</sup>, Notch1 $\Delta$ E<sup>S1791E</sup> or Notch1 $\Delta$ E. The graph (below) shows the quantification of nuclear levels of NICD from three different experiments. **(C)** The ratio of cells containing nuclear Notch immunoreactivity to all cells with Notch immunoreactivity (nuclear+cytoplasmic) in cells transfected with Notch1 $\Delta$ E, Notch1 $\Delta$ E<sup>S1791A</sup> or Notch1 $\Delta$ E<sup>S1791E</sup>. **(D)** Representative microscopy images showing the colocalization of Notch1 $\Delta$ E<sup>S1791A</sup> or Notch1 $\Delta$ E<sup>S1791E</sup> with Rab5 and Rab7. **(E)** Immunoprecipitation of Notch1 from 293 HEK cells transfected with either wild-type or mutant Notch1 $\Delta$ E and GFP-Rab5 or GFP-Rab7. Immunoblotting was performed with an antibody against GFP. **(F)** Immunoprecipitation of Lamp1 from 293 HEK cells transfected with Notch1 $\Delta$ E, Notch1 $\Delta$ E<sup>S1791A</sup> or Notch1 $\Delta$ E<sup>S1791E</sup>. **(G)** Confluent C2C12 cells treated with siRNA against PKC $\zeta$  (siPKC $\zeta$ ) or control (siScr) were lysed and subjected to immunoprecipitation using a Lamp1 antibody. Immunoblotting was performed with an antibody against Notch1 to detect NEXT. **(H)** Immunofluorescence images showing the localization of Notch1 in C2C12 cells. The late endosomal/lysosomal marker Lamp1 versus the early/sorting endosomal markers EEA1 and FYVE in cells treated with the PKC $\zeta$  inhibitor (PS). Scale bars, 10  $\mu$ m.






**Figure 6** Regulation of Notch1 by PKC $\zeta$  affects myoblast differentiation. **(A)** Western blot of primary myoblasts treated with the PKC $\zeta$ -inhibitory peptide (PS) or a scrambled control peptide (Scr-P) demonstrates that the level of NICD is reduced by PS. **(B)** Immunocytochemistry of control and PS-treated primary myoblasts at 0 and 48 h of differentiation, using antibodies against nestin and MHC. **(C)** Western blot of C2C12 cells treated with siRNA against PKC $\zeta$  (siPKC $\zeta$ ) or control at different time points of differentiation. The antibodies used are indicated to the right. PKC $\zeta$  knockdown in this experiment was 50%. **(D)** Western blot of C2C12 cells transfected with caPKC $\zeta$  or control at different time points of differentiation. **(E)** Representative microscopy images showing the expression of Notch1 and MHC in C2C12 cells transfected with Notch1 $\Delta$ E or Notch1 $\Delta$ E<sup>S1791A</sup> (shown in green) at 48 h after induction of differentiation. Notch1 $\Delta$ E and Notch1 $\Delta$ E<sup>S1791A</sup> are seen in green. The stars denote cells expressing Notch1 $\Delta$ E or Notch1 $\Delta$ E<sup>S1791A</sup> and have differentiated based on the expression of the differentiation marker MHC. The percentage of positive cells for the different experiments is listed below. Scale bars, 20  $\mu$ m **(B)**, 50  $\mu$ m **(E)**.

ceptor is not activated, i.e., in cells cultured very sparsely and thus not engaged in cell-cell contact, PKC $\zeta$  interacts with the receptor to induce a shift in receptor distribution from the plasma membrane to intracellular vesicles, a transition which is not accompanied by enhanced Notch signaling.

We present several lines of evidence supporting the notion that PKC $\zeta$  under active Notch signaling promotes S3 cleavage of membrane-tethered forms of Notch1 that are localized to late endosomes, which results in libera-

tion of NICD and its nuclear entry. First, knockdown of endogenous PKC $\zeta$  enhanced the interaction of Notch1 with Lamp1, a marker for late endosomes/lysosomes and blocking of PKC $\zeta$  in the CNS *in vivo* reduced the number of cells with nuclear Notch1. Second, expression of a constitutively active PKC $\zeta$  shifted the Notch1 distribution from endosomes to the nucleus. In keeping with this, elevated PKC $\zeta$  activity resulted in increased Notch signaling output, indicative of increased presence of NICD in the nucleus. Third, the identification of S1791



as the key PKC $\zeta$  phosphorylation site in Notch1 allowed us to test the effects of phosphomimetic and phosphorylation-deficient mutants of Notch1, which were congruent with enhancement and reduction of PKC $\zeta$  activity, respectively. Indeed, expression of the phosphomimetic Notch1 $\Delta E^{S1791E}$  resulted in re-localization of Notch immunoreactivity from intracellular vesicles to the nucleus, enhanced NICD production and Notch signaling. In contrast, the phosphorylation-deficient Notch1 $\Delta E^{S1791A}$  yielded the opposite phenotype, i.e., accumulation in intracellular vesicles, less NICD production and Notch signaling. The notion that Notch processing is actively controlled in the late endosome compartment is corroborated by earlier reports that mutations in ESCRT proteins, which regulate endocytic sorting and further transition to lysosomes, led to endosomal accumulation of Notch and enhanced Notch signaling [53, 54].

In the non-activated state, PKC $\zeta$  affects Notch receptor routing in a different manner. Notch is shifted from the cell surface to intracellular vesicles. The observation that PKC $\zeta$  was associated with the full-length Notch1 prior to  $\gamma$ -secretase cleavage supports the view that PKC $\zeta$  can control Notch in the non-activated state. It is interesting to note that membrane-tethering of the receptor appeared to be a prerequisite for PKC $\zeta$  binding and phosphorylation; an NICD without a transmembrane domain did not interact with PKC $\zeta$ , and was also not phosphorylated. Increased internalization of Notch1 by PKC $\zeta$  in the non-activated state is further supported by an enhanced interaction of Notch1 with Hrs, a protein localized in early endosomes/multivesicular bodies. While it may appear reasonable to surmise that internalization

of Notch receptors by PKC $\zeta$  would be associated with increased signaling, we did not observe an increase in the amount of NICD or in the immediate downstream signaling. In the light of increased receptor internalization, we unexpectedly did not observe a decrease in biotinylation of Notch receptors at cell surface upon expression of a constitutively active PKC $\zeta$ . We currently cannot explain this finding, but the data raise the intriguing possibility that non-activated Notch receptors may be recycled back to the cell surface from endosomes rather than being degraded in lysosomes. PKC $\zeta$  may then shift the balance towards the endosomal localization at the expense of cell surface localization rather than blocking the recycling process *per se*. This would be compatible with the data on Notch1 localization and Hrs interaction, and a continued recycling may also explain why cell surface labeling of Notch1 was not reduced and why there was no increase in lysosomal degradation.

Different from other proteins known to affect Notch intracellular routing, PKC $\zeta$  acts at two distinct steps in receptor trafficking depending on the activation state of Notch, i.e., shifting Notch from cell surface to early endosomes in the non-activated state and from late endosomes to nucleus in the activated state. The distinct activation-dependent outcomes may explain why endocytosis in certain situations enhances Notch signaling, while in other settings it downregulates Notch signaling [4–12]. Our data show that PKC $\zeta$  not only modulates Notch1 localization and signaling activity, but also exerts an effect on Notch-controlled differentiation processes. Inhibition of PKC $\zeta$  abrogated Notch1-mediated block of differentiation in the developing CNS. Ossipova *et al.* [40] have

**Figure 7** aPKC regulates localization of Notch1 in the non-activated state. **(A)** Representative microscopy images showing localization of Notch1 and PKC $\zeta$  in a Notch signaling off state. 293FLN1 cells were cultured sparsely and transfected with caPKC $\zeta$  or control vector. The cells were stained with antibodies against Notch1 (green) and PKC $\zeta$  (red), and counterstained with DAPI. **(B)** Representative microscopy images showing localization of Notch1 and PKC $\zeta$  in C2C12 cells expressing full-length Notch1 transfected with caPKC $\zeta$  or empty vector. The cells were stained with antibodies against Notch1 and PKC $\zeta$ , and counterstained with DAPI. **(C)** Quantification of the internalization of the receptor using a fluorescently labeled recombinant peptide Jagged1 extracellular domain which binds to the extracellular domain of Notch. Quantification was performed by flow cytometry. The number above the bars denotes the percentage of positive cells, i.e., cells which have internalized the fluorescent peptide and show positive fluorescence. These cells were gated and MFI denotes mean fluorescence intensity, i.e., mean intensity per cell within the gated population (in this case 79.8% of mock and 68.4% of caPKC $\zeta$  were gated). **(D)** Upper, western blot using an antibody against NICD in 293FLN1 cells transfected with increasing amounts of caPKC $\zeta$ . Lower, Notch signaling activity in 293FLN1 cells transfected with increasing amounts of PKC $\zeta$  and a control vector. **(E)** Immunoprecipitation using an antibody against Notch1 in HeLa cells transfected with Notch1 $\Delta E$ , HA-tagged ubiquitin (Ub-HA) and caPKC $\zeta$ , caPKC $\iota$  or empty vector. The cells were subjected to a 24-h treatment with chloroquine prior to harvesting. Immunoblotting was performed with an antibody recognizing the HA-tag, for the input an antibody against Notch1 was used. **(F)** Immunoprecipitation with an antibody against the endosome-associated ubiquitin-binding protein Hrs in HeLa cells transfected with Notch1 $\Delta E$  and caPKC $\zeta$  or empty vector. Cells were treated with chloroquine or vehicle control 24 h prior to harvesting. Immunoblotting was performed using an antibody against Notch1. **(G)** Western blotting showing Notch1 levels in 293FLN1 cells transfected with caPKC $\zeta$  or empty vector and treated with chloroquine or vehicle control 24 h prior to harvesting. **(H)** Immunoblot using a Notch1 antibody on streptavidin immunoprecipitates of biotin-labeled surface Notch1. Scale bars in **A** and **B**, 10  $\mu$ m.



previously demonstrated that PKC $\zeta$  suppresses neuronal differentiation, which is in line with the results presented here. They showed that PKC negatively regulates PAR-1, which in turn blocks the function of the E3 ubiquitin ligase Mindbomb, thereby enhancing the level of Dll1 ligands. While this can clearly lead to blocked neurogenesis, it is mechanistically distinct from the direct action of aPKC on Notch1 presented here.

In C2C12 myoblasts, PKC $\zeta$  enhanced Notch signaling, in keeping with a Notch signaling-promoting role of PKC $\zeta$  when Notch signaling is engaged, and reduced differentiation to MHC-positive myotubes under differentiation-promoting conditions. Conversely, pharmacological inhibition of PKC $\zeta$  led to precocious differentiation of myotubes and reduced levels of NICD. Similarly, a phosphodeficient Notch1 $\Delta$ E increased the proportion of differentiated cells, as compared to wild-type Notch1 $\Delta$ E. These observations add to an emerging view of PKC $\zeta$  as an important regulator of cell differentiation in various settings [40, 55, 56]. The influence of PKC $\zeta$  on differentiation is multifaceted and we have previously demonstrated that PKC $\zeta$  is required for fusion and terminal differentiation of myoblasts through the regulation of Caspase-3 and Cdk5/p35 kinase [39]. It is interesting to note that in the present study, PKC $\zeta$  plays a differentiation-inhibiting role at the earlier stages of myogenic differentiation when Notch signaling is active.

In conclusion, the data presented here shed new light on Notch receptor intracellular routing and identifies PKC $\zeta$  as a key controller of distinct steps in Notch receptor trafficking. In addition to providing a new regulatory mechanism for Notch signaling, the newly discovered link between aPKC and Notch may also be important to be taken into consideration when pharmacologically intervening with aPKC function in diseases, as such approaches may inadvertently impinge on Notch signaling.

## Materials and Methods

### Cell culture

Mouse C2C12 myoblasts, human embryonic kidney 293 cells (293 HEK) and cervical cancer HeLa cells were grown in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine, penicillin (100 U/ml) and streptomycin (100  $\mu$ g/ml). Differentiation of C2C12 myoblasts was induced by replacing the cell culture medium with differentiation medium (DMEM supplemented with 1% FBS, 2 mM glutamine, penicillin (100 U/ml) and streptomycin (100  $\mu$ g/ml)). The  $\gamma$ -secretase inhibitor DAPT was used at a concentration of 5  $\mu$ g/ml. The concentrations of lysosomal inhibitor chloroquine and the proteasomal inhibitor MG132 were 20  $\mu$ M. The dynamin inhibitor Dynasore was used at a concentration of 80  $\mu$ M. To inhibit PKC $\zeta$  activity, cells were grown in the presence of 20  $\mu$ M pseudosubstrate inhibitor peptide (PS; Myr-SIYRRGARRWRKL)

or control scrambled peptide (Scr-P; Myr-RLYRKRIWRSAGR; MilleGen Prologue Biotech, Labege Cedex, France). Alternatively, PKC $\zeta$  was downregulated by siRNA. Note that the timing of the treatment/downregulation was adjusted to inhibit PKC $\zeta$  activity under conditions of active Notch signaling.

### *In vivo analysis of chick CNS development*

DNA constructs were electroporated into the caudal neural tube of HH stage 10 chick embryos. After 24–40 h, embryos were fixed and processed for immunohistochemistry. In the cohort of embryos in which PKC $\zeta$  activity was to be inhibited, 20  $\mu$ M pseudosubstrate inhibitor peptide was included in the DNA mix prior to electroporation. Images were acquired with a Zeiss Axiovert microscope fitted with a LSM5 Exciter confocal unit. The objectives used were Plan Apochromat 10 $\times$  and 20 $\times$  objectives with apertures of 0.45 and 0.8, respectively. The Zeiss LSM Imaging software was utilized for image acquisition. Images were processed in Adobe Photoshop (AS5). Contrast enhancement of the images was performed utilizing the tool "Levels" in AS5. The images of the different experimental groups were processed in an identical manner. The fluorochromes used were Alexa 555, and Alexa 647 from Life Technologies.

### *Primary mouse myoblast culture*

Cultures of primary myoblasts were established from the limb skeletal muscles of two-day-old FVB/N mice. Muscle tissue was minced and enzymatically digested by incubation in 0.2% (wt/vol) type XI collagenase (Roche Diagnostics, Basel, Switzerland) and 0.1% (wt/vol) trypsin at 37  $^{\circ}$ C for 45 min. The resulting slurry was filtered to remove large pieces of tissue and rinsed with growth medium as follows: Ham's F-10 (Sigma-Aldrich, St Louis, MO, USA) supplemented with 15% (vol/vol) FBS, 2 mM glutamine, penicillin G (100 U/ml)/streptomycin (100  $\mu$ g/ml) and 2.5 ng/ml  $\beta$ -FGF (fibroblast growth factor). Cells were centrifuged at 1 000 $\times$  g for 5 min, resuspended in growth medium and seeded into tissue culture dishes. After attainment of 80% confluence, differentiation was induced by replacing growth medium with differentiation medium as follows: DMEM supplemented with 2% (vol/vol) FBS, 2 mM glutamine and penicillin G (100 U/ml)/streptomycin (100  $\mu$ g/ml).

### *Transfection*

For transfection, HeLa and 293 HEK cells were pelleted and resuspended in Opti-MEM (Invitrogen) together with the desired plasmid and electroporated at 220 V and 975  $\mu$ F. The transfected cells were plated and harvested after 24 h for further analysis. C2C12 myoblasts were transfected using jetPEI transfection reagent (Polyplus transfections) according to the manufacturer's instructions.

### *Western blotting*

Proteins were separated by SDS-PAGE and transferred to a Protran nitrocellulose membrane (Perkin Elmer) using a wet transfer apparatus (Amersham Biosciences). Non-specific binding was blocked by incubating the membranes in 5% non-fat dry milk at room temperature (RT) for 1 h. Membranes were incubated with primary antibody overnight at 4  $^{\circ}$ C, followed by incubation with a secondary antibody coupled to horseradish peroxidase for 1 h at RT. Proteins were detected using Western Lightning $^{\circ}$  Plus-

ECL Enhanced chemiluminescence substrate (Perkin Elmer, MA, USA), according to the manufacturer's instructions.

### Antibodies and constructs

The following antibodies were used: PKC (C20 rabbit) (Santa Cruz Biotechnology),  $\beta$ -actin (rabbit) (Cell Signaling Technology), Cleaved Notch1 (rabbit Val1744) (Cell Signaling Technology), Notch1 (Cleaved-Val-1744 rabbit) (Sigma Aldrich), HA.11 (mouse) (Covance), Hsc70 (rat 1B5) (StressGen), GFP (rabbit JL-8) (Clontech),  $\alpha$ -GFP (rabbit) (Invitrogen), Lamp1 (mouse H4A3) (Abcam), Myosin heavy chain (rabbit H-300) (Santa Cruz Biotechnology), Notch1 (C20 rabbit for western blot and goat for IP) (Santa Cruz Biotechnology). Fluorescent secondary antibodies: Alexa Fluor 555 donkey anti-goat IgG, Alexa Fluor 488 donkey anti-goat IgG, Alexa Fluor 488 donkey anti-rabbit IgG, Alexa Fluor 546 donkey anti-rabbit IgG, Alexa Fluor 488 Donkey anti-goat IgG 488 (Invitrogen). GFP-Rab5, Lamp1-GFP and GFP-Rab7 were kind gifts from Dr J Ivaska (VTT, Turku, Finland), GFP-Fyve and GFP-EEA1 have been previously described. The table in Supplementary information, Figure S2 denotes the proteolytic processing and the respective products of endogenous Notch1 in the pathway, the different Notch1 constructs and their immunoreactivity.

### Immunoprecipitation

Cells were lysed in immunoprecipitation buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% deoxycholic acid, 0.05% SDS, 5 mM EDTA, 5 mM EGTA and protease inhibitor (Complete protease inhibitor cocktail, Roche)) for 30 min on ice, followed by centrifugation at 15 000 $\times$  g for 10 min at 4 °C. Lysates were pre-cleared by incubating with a small amount of protein G dynabeads (Invitrogen) on rotation at 4 °C for 1 h. Immunoprecipitation was conducted with the denoted antibodies (C20 goat IgG for Notch and cleaved Notch1 (Val1744) for NICD) overnight at 4 °C. Immunocomplexes were captured by addition of protein G dynabeads and incubation for 2 h at 4 °C, washed three times with immunoprecipitation buffer and resuspended in Laemmli Sample buffer for analysis.

Alternatively, cells were lysed in immunoprecipitation buffer (50 mM HEPES, pH 7.4, 140 mM NaCl, 5 mM MgCl<sub>2</sub>, 5 mM EGTA, 0.4% (vol/vol) NP-40, 10 mM pyrophosphate, 5 mM sodium orthovanadate and a protease inhibitor cocktail (Roche Diagnostics) for 30 min on ice followed by centrifugation at 12 000 $\times$  g for 10 min at 4 °C. Protein concentration was measured by the Bradford assay, and 800  $\mu$ g of each lysate was pre-cleared using Sepharose beads, for 45 min, followed by immunoprecipitation with the indicated antibodies. Immunocomplexes were captured on protein G-Sepharose beads, washed four times in 20 mM HEPES, pH 7.4, 2 mM EGTA, 100 mM NaCl, 0.4% (vol/vol) NP-40, and 1 mM dithiothreitol (DTT), and finally resuspended in Laemmli sample buffer.

### Immunocytochemistry

Cells grown on cover slips were fixed in 3% paraformaldehyde and permeabilized with 0.1% Triton X-100 in PBS for 5 min at RT. Non-specific binding sites were blocked by incubation in 3% bovine serum albumin (BSA) in PBS with 0.05% Triton X-100 for 30-60 min at RT. Cells were stained with primary antibodies overnight at 4 °C or 2 h at RT, after which coverslips were rinsed three times with PBS and stained for 40-60 min with fluorescence tag-labeled secondary antibodies. Cells were counterstained

with DAPI and washed three times in PBS before mounting with Prolong Gold (Invitrogen). Images were collected using a Zeiss LSM510 META laser scanning microscope. Images were processed in Adobe Photoshop (CS5). Contrast enhancement of the images was performed utilizing the tool "Levels" in AS5. The images of the different experimental groups were processed in an identical manner. The fluorochromes used were Alexa 488, 555 and Alexa 647 from Life Technologies.

### Luciferase reporter assay

Cells stably expressing the full-length Notch receptor were transfected with 12 $\times$ CSL-luc and CMV- $\beta$ -galactosidase using electroporation. Depending on the experiment, cells were also co-transfected with Notch1 $\Delta$ E, Notch1 $\Delta$ E<sup>S1791A</sup>, Notch1 $\Delta$ E<sup>S1769E</sup>, NICD and caPKC $\zeta$ . Twenty-four hours later, the cells were lysed in Cell culture lysis reagent (Promega) and analyzed for luciferase activity using a Luciferase assay system (Promega) with a Luminoskan ascent microplate luminometer (Thermo Scientific).  $\beta$ -galactosidase activity is measured using a Multiskan ascent (Thermo Scientific).

### Activation of Notch signaling by immobilized recombinant Notch ligands

Cell culture plates were coated with 50  $\mu$ g/ml Protein G (Zymed) in PBS at RT overnight. The plates were washed three times with PBS and blocked with 10 mg/ml BSA in PBS for 2 h at RT. The blocked plates were washed three times with PBS and incubated with recombinant Jagged1-FC chimera (R&D Systems) or Fc-IgG (Jackson ImmunoResearch) at concentrations of 0.5  $\mu$ g/ml in 0.1% BSA/PBS for 2 h at RT. Alternatively, conditioned medium from 293 HEK cells expressing soluble Dll1 was used as a source for immobilized ligand. After final washing with PBS and cell culture medium, the cells were plated on the coated plates and harvested for analysis 24 h later.

### Ubiquitylation assay

The cells were pelleted and suspended in ice-cold PBS. Pre-heated 1% SDS in PBS was added and the samples were boiled for 7 min. The samples were further suspended in 1% Triton X-100, 0.5% BSA in PBS and sonicated, followed by centrifugation at 10 000 $\times$  g for 10 min at 4 °C. Finally, the samples were immunoprecipitated with the indicated antibodies as described previously.

### Biotinylation assay

Cells were placed on ice and washed with cold PBS. Surface proteins were labeled with 0.5 mg/ml EZ-link sulfo-NHS-SS-biotin in PBS for 30 min at 4 °C. The cells were washed three times with cold 0.1 M glycine in PBS, followed by three washes with cold PBS. The cells were pelleted by scraping in immunoprecipitation buffer containing protease inhibitors and incubated on ice for 10 min. The lysates were centrifuged at 15 000 rpm for 10 min at 4 °C and the supernatant was collected. EZ-link sulfo-NHS-SS-biotin-labeled proteins were immunoprecipitated by incubating with Streptavidine agarose beads at 4 °C on rotation. The pellets were washed three times with immunoprecipitation buffer before resuspension in Laemmli Sample buffer for analysis by SDS-PAGE.

### In vitro phosphorylation and kinase activity assays

*In vitro* phosphorylation assays were performed using immunoprecipitated Notch as substrates. Cell lysates were incubated

with Notch antibody (C20) for 1 h and subsequently with protein G-Sepharose beads for 45 min. Immunoprecipitates were washed for four times in 50 mM HEPES (pH 7.4), 5 mM EDTA, 125 mM NaCl, 0.2% (v/v) NP-40 and 1 mM DTT, and twice with 50 mM HEPES (pH 7.4), 25 mM NaCl and 1 mM DTT, and resuspended in PKC $\zeta$  kinase buffer (50 mM HEPES, pH 7.4, 1 mM EDTA, 1 mM DTT, 10 mM MgCl<sub>2</sub>) with 200  $\mu$ M unlabeled ATP, 10  $\mu$ Ci ( $\gamma$ -<sup>32</sup>P)-ATP and 50 ng recombinant PKC $\zeta$  (Upstate Biotechnology, New York, USA). The reaction was allowed to proceed for 30 min at 32 °C. Reactions were stopped by addition of Laemmli sample buffer and boiling for 5 min. Gels were stained with Coomassie Blue, dried and subjected to autoradiography. As loading controls, 8  $\mu$ l aliquotes of immunoprecipitates were subjected to SDS-PAGE, transferred to nylon membranes, stained with Red Ponceau and visualized using the ECL Western blotting kit (Amersham). Identification of phosphorylation sites by mass spectrometry is described in Supplementary information, Figure S3.

### Receptor internalization by FACS

293FLN1 cells were transfected with caPKC $\zeta$  or control vector and plated on 12-well plates. The following day recombinant rat Jagged1-FC chimera (R&D systems, Cat# 599-JG) (1  $\mu$ g/ml) and Alexa Fluor 488 goat anti-human IgG (Invitrogen, Cat# A11013) (1:200) were diluted in sterile PBS and incubated on rotation at 4 °C for 1 h. Simultaneously, the cells were blocked with DMEM containing 10% goat serum and 1 % BSA for 45 min at 37 °C. The Jagged FC-Alexa 488 solution was further diluted in blocking solution at a ratio of 1:5 and this solution was added to the cells, followed by incubation at 37 °C for 2 h. The cells were then detached, centrifuged (450 $\times$  g, 5 min) and quenched with 200  $\mu$ g/ml trypan blue in PBS for 5 min at RT. Next, the cells were centrifuged again and excess trypan blue was removed. The cells were finally resuspended in PBS and analyzed by FACS.

### Acknowledgments

This work was supported by Academy of Finland (CS, SYI), Center of Excellence in Cell stress and Molecular Aging, Åbo Akademi (DA), Turku Graduate School for Biomedical Sciences (MS), the Swedish Cancer Society, the Swedish Research Council (DBRM, StratRegen and Project Grant), Karolinska Institute (BRECT, Theme Center in Regenerative Medicine and a Distinguished Professor Award to UL). We are grateful to Helena Saarento for technical assistance. We thank the Cell Imaging Core at Turku Centre for Biotechnology and the proteomics facility of the MRC Protein Phosphorylation Unit, University of Dundee.

### References

- Andersson ER, Sandberg R, Lendahl U. Notch signaling: simplicity in design, versatility in function. *Development* 2011; **138**:3593-3612.
- Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the activation mechanism. *Cell* 2009; **137**:216-233.
- Yamamoto S, Charng W-L, Bellen HJ. Endocytosis and intracellular trafficking of Notch and its ligands. *Curr Top Dev Biol* 2010; **92**:165-200.
- Gupta-Rossi N, Six E, LeBail O, *et al.* Monoubiquitination and endocytosis direct gamma-secretase cleavage of activated Notch receptor. *J Cell Biol* 2004; **166**:73-83.
- Nichols JT, Miyamoto A, Weinmaster G. Notch signaling-constantly on the move. *Traffic* 2007; **8**:959-969.
- Seugnet L, Simpson P, Haenlin M. Requirement for dynamin during Notch signaling in *Drosophila* neurogenesis. *Dev Biol* 1997; **192**:585-598.
- Vaccari T, Lu H, Kanwar R, Fortini ME, Bilder D. Endosomal entry regulates Notch receptor activation in *Drosophila* melanogaster. *J Cell Biol* 2008; **180**:755-762.
- Berdnik D, Török T, González-Gaitán M, Knoblich JA. The endocytic protein alpha-Adaptin is required for numb-mediated asymmetric cell division in *Drosophila*. *Dev Cell* 2002; **3**:221-231.
- Childress JL, Acar M, Tao C, Halder G. Lethal giant discs, a novel C2-domain protein, restricts notch activation during endocytosis. *Curr Biol* 2006; **16**:2228-2233.
- Gallagher CM, Knoblich JA. The conserved c2 domain protein lethal (2) giant discs regulates protein trafficking in *Drosophila*. *Dev Cell* 2006; **11**:641-653.
- Shaye DD, Greenwald I. Endocytosis-mediated downregulation of LIN-12/Notch upon Ras activation in *Caenorhabditis elegans*. *Nature* 2002; **420**:1-5.
- Sorensen EB, Conner SD.  $\gamma$ -secretase-dependent cleavage initiates notch signaling from the plasma membrane. *Traffic* 2010; **11**:1234-1245.
- Gupta-Rossi N, Ortica S, Meas-Yedid V, *et al.* The adaptor-associated kinase 1, AAK1, is a positive regulator of the Notch pathway. *J Biol Chem* 2011; **286**:18720-18730.
- Vaccari T, Duchi S, Cortese K, Tacchetti C, Bilder D. The vacuolar ATPase is required for physiological as well as pathological activation of the Notch receptor. *Development* 2010; **137**:1825-1832.
- Tagami S, Okochi M, Yanagida K, *et al.* Regulation of Notch signaling by dynamic changes in the precision of S3 cleavage of Notch-1. *Mol Cell Biol* 2008; **28**:165-176.
- Yan Y, Deneff N, Schüpbach T. The vacuolar proton pump, V-ATPase, is required for notch signaling and endosomal trafficking in *Drosophila*. *Dev Cell* 2009; **17**:387-402.
- Moretti J, Chastagner P, Gastaldello S, *et al.* The translation initiation factor 3f (eIF3f) exhibits a deubiquitinase activity regulating Notch activation. *PLoS Biol* 2010; **8**:e1000545.
- Mukherjee A, Veraksa A, Bauer A, Rosse C, Camonis J, Artavanis-Tsakonas S. Regulation of Notch signalling by non-visual beta-arrestin. *Nat Cell Biol* 2005; **7**:1191-1201.
- Sestan N. Contact-dependent inhibition of cortical neurite growth mediated by notch signaling. *Science* 1999; **286**:741-746.
- Wilkin M, Tongngok P, Gensch N, *et al.* *Drosophila* HOPS and AP-3 complex genes are required for a Deltex-regulated activation of notch in the endosomal trafficking pathway. *Dev Cell* 2008; **15**:762-772.
- Fortini ME, Bilder D. Endocytic regulation of Notch signaling. *Curr Opin Genet Dev* 2009; **19**:323-328.
- McGill MA, Dho SE, Weinmaster G, McGlade CJ. Numb regulates post-endocytic trafficking and degradation of Notch1. *J Biol Chem* 2009; **284**:26427-38.
- Le Borgne R, Bardin A, Schweisguth F. The roles of receptor



- and ligand endocytosis in regulating Notch signaling. *Development* 2005; **132**:1751-1762.
- 24 Bilder D. Epithelial polarity and proliferation control: links from the *Drosophila* neoplastic tumor suppressors. *Genes Dev* 2004; **18**:1909-1925.
- 25 Galli M, Muñoz J, Portegijs V, *et al.* aPKC phosphorylates NuMA-related LIN-5 to position the mitotic spindle during asymmetric division. *Nat Cell Biol* 2011; **13**:1132-1138.
- 26 Atwood SX, Prehoda KE. aPKC phosphorylates Miranda to polarize fate determinants during neuroblast asymmetric cell division. *Curr Biol* 2009; **19**:723-729.
- 27 Lee CY, Andersen RO, Cabernard C, *et al.* *Drosophila* Aurora-A kinase inhibits neuroblast self-renewal by regulating aPKC/Numb cortical polarity and spindle orientation. *Genes Dev* 2006; **20**:3464-3474.
- 28 Nishimura T, Kaibuchi K. Numb controls integrin endocytosis for directional cell migration with aPKC and PAR-3. *Dev Cell* 2007; **13**:15-28.
- 29 Rosse C, Formstecher E, Boeckeler K, *et al.* An aPKC-exocyst complex controls paxillin phosphorylation and migration through localised JNK1 activation. *PLoS Biol* 2009; **7**:e1000235.
- 30 Zhou P, Alfaro J, Chang EH, Zhao X, Porcionatto M, Segal R A. Numb links extracellular cues to intracellular polarity machinery to promote chemotaxis. *Dev Cell* 2011; **20**:610-622.
- 31 Cui S, Otten C, Rohr S, Abdelilah-Seyfried S, Link BA. Analysis of aPKC $\lambda$  and aPKC $\zeta$  reveals multiple and redundant functions during vertebrate retinogenesis. *Mol Cell Neurosci* 2007; **34**:431-444.
- 32 McCaffrey LM, Macara IG. The Par3/aPKC interaction is essential for end bud remodeling and progenitor differentiation during mammary gland morphogenesis. *Genes Dev* 2009; **23**:1450-1460.
- 33 Tabler JM, Yamanaka H, Green JB. PAR-1 promotes primary neurogenesis and asymmetric cell divisions via control of spindle orientation. *Development* 2010; **137**:2501-2505.
- 34 Williams SE, Beronja S, Pasolli HA, Fuchs E. Asymmetric cell divisions promote Notch-dependent epidermal differentiation. *Nature* 2011; **470**:353-358.
- 35 Georgiou M, Marinari E, Burden J, Baum B. Cdc42, Par6, and aPKC regulate Arp2/3-mediated endocytosis to control local adherens junction stability. *Curr Biol* 2008; **18**:1631-1638.
- 36 Georgiou M, Baum B. Polarity proteins and Rho GTPases cooperate to spatially organise epithelial actin-based protrusions. *J Cell Sci* 2010; **123**:1389-1398.
- 37 Leibfried A, Fricke R, Morgan MJ, Bogdan S, Bellaiche Y. *Drosophila* Cip4 and WASp define a branch of the Cdc42-Par6-aPKC pathway regulating E-cadherin endocytosis. *Curr Biol* 2008; **18**:1639-1648.
- 38 Sato K, Watanabe T, Wang S, *et al.* Numb controls E-cadherin endocytosis through p120 catenin with aPKC. *Mol Biol Cell* 2011; **22**:3103-3119.
- 39 Thonell D, Ferraris SE, Pallari H, *et al.* Protein kinase C regulates Cdk5/p25 signaling during. *Mol Biol Cell* 2010; **21**:1423-1434.
- 40 Ossipova O, Ezan J, Sokol SY. PAR-1 phosphorylates Mind bomb to promote vertebrate neurogenesis. *Dev Cell* 2009; **17**:222-233.
- 41 Balklava Z, Pant S, Fares H, Grant BD. Genome-wide analysis identifies a general requirement for polarity proteins in endocytic traffic. *Nat Cell Biol* 2007; **9**:1066-1073.
- 42 Shivas JM, Morrison HA, Bilder D, Skop AR. Polarity and endocytosis: reciprocal regulation. *Trends Cell Biol* 2010; **20**:445-452.
- 43 Holmberg J, Hansson E, Malewicz M, *et al.* SoxB1 transcription factors and Notch signaling use distinct mechanisms to regulate proneural gene function and neural progenitor differentiation. *Development* 2008; **135**:1843-51.
- 44 Hansson EM, Teixeira AI, Gustafsson MV, *et al.* Recording Notch signaling in real time. *Dev Neurosci* 2006; **28**:118-127.
- 45 Chapman G, Liu L, Sahlgren C, Dahlqvist C, Lendahl U. High levels of Notch signaling down-regulate Numb and Numlike. *J Cell Biol* 2006; **175**:535-540.
- 46 Macia E, Ehrlich M, Massol R, Boucrot E, Brunner C, Kirchhausen T. Dynasore, a cell-permeable inhibitor of dynamin. *Dev Cell* 2006; **10**:839-850.
- 47 Gulino A, Di Marcotullio L, Screpanti I. The multiple functions of Numb. *Exp Cell Res* 2010; **316**:900-906.
- 48 Couturier L, Vodovar N, Schweisguth F. Endocytosis by Numb breaks Notch symmetry at cytokinesis. *Nat Cell Biol* 2012; **14**:131-139.
- 49 Smith CA, Lau KM, Rahmani Z, *et al.* aPKC-mediated phosphorylation regulates asymmetric membrane localization of the cell fate determinant Numb. *EMBO J* 2007; **26**:468-480.
- 50 Stenmark H. Rab GTPases as coordinators of vesicle traffic. *Nat Rev Mol Cell Biol* 2009; **10**:513-525.
- 51 Dahlqvist C, Blokzijl A, Chapman G, *et al.* Functional Notch signaling is required for BMP4-induced inhibition of myogenic differentiation. *Development* 2003; **130**:6089-6099.
- 52 Nofziger D, Miyamoto A, Lyons KM, Weinmaster G. Notch signaling imposes two distinct blocks in the differentiation of C2C12 myoblasts. *Development* 1999; **126**:1689-1702.
- 53 Thompson BJ, Mathieu J, Sung HH, Loeser E, Rørth P, Cohen SM. Tumor suppressor properties of the ESCRT-II complex component Vps25 in *Drosophila*. *Dev Cell* 2005; **9**:711-720.
- 54 Vaccari T, Bilder D. The *Drosophila* tumor suppressor vps25 prevents nonautonomous overproliferation by regulating notch trafficking. *Dev Cell* 2005; **9**:687-698.
- 55 Solecki DJ, Model L, Gaetz J, Kapoor TM, Hatten ME. Par6 $\alpha$  signaling controls glial-guided neuronal migration. *Nat Neurosci* 2004; **7**:1195-1203.
- 56 Solecki DJ, Govek EE, Tomoda T, Hatten ME. Neuronal polarity in CNS development. *Genes Dev* 2006; **20**:2639-2647.

(Supplementary information is linked to the online version of the paper on the Cell Research website.)